Inhibrx Biosciences, Inc.
INBX
$29.59
$0.4851.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -163.69M | 1.72B | 1.69B | 1.64B | 1.63B |
| Total Depreciation and Amortization | 2.79M | 2.60M | 2.29M | 1.89M | 1.44M |
| Total Amortization of Deferred Charges | 1.16M | 1.36M | 2.07M | 3.31M | 4.55M |
| Total Other Non-Cash Items | 13.01M | -1.94B | -1.94B | -1.93B | -1.93B |
| Change in Net Operating Assets | 6.89M | 48.18M | 52.05M | 80.40M | 60.07M |
| Cash from Operations | -139.85M | -167.25M | -194.41M | -207.51M | -231.47M |
| Capital Expenditure | -284.00K | -1.50M | -2.60M | -6.02M | -6.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -284.00K | -1.50M | -2.60M | -6.02M | -6.59M |
| Total Debt Issued | 99.97M | 99.97M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 32.95M | 71.68M | 72.76M | 272.78M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -125.00K | -125.00K | -- | -225.00K | -355.00K |
| Cash from Financing | 99.84M | 132.79M | 71.68M | 72.54M | 272.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.29M | -35.96M | -125.33M | -141.00M | 34.37M |